person
as of 2026-07-01Christoph U. Correll, MD
Christoph Correll, MDChristoph U CorrellChristoph U Correll, MD
ORCID 0000-0002-7254-5646
at a glance
Roles: Principal Investigator, Study Chair, Study Director, Author, Investigator+Author
KOL signal score 96
44 publications · 20 high-value
Cross-drug reach: 7 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
The Zucker Hillside Hospital
Roles
Principal Investigator, Study Chair, Study Director, Author, Investigator+Author
KOL signal
96
Publications
44 (20 high-value)
Trial investigator
yes
Publishes on
7 drugs
Trials led
6
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
NCT00169988—Completed
Treating Drug-Resistant Childhood Schizophrenia
NCT00048828Phase 4Completed
Adjunctive Vortioxetine in Schizophrenia
NCT02357797Phase 4Unknown
Clinical Risk State for Bipolar Disorder in Adolescents
NCT01383915—Unknown
Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
NCT00806234Phase 4Completed
Publications & congress
34
Guidelines for the prevention of psychosis from the World Federation of Societies of Biological Psychiatry (WFSBP) and EPI Canada.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2026 · high-value
The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia.
The Journal of clinical psychiatry · 2026 · high-value
Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.
International clinical psychopharmacology · 2026 · high-value
Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents.
Psychiatry research · 2026 · high-value
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference.
The lancet. Psychiatry · 2025 · high-value
Antipsychotic-Related Prolactin Changes: A Systematic Review and Dose-Response Meta-analysis.
CNS drugs · 2025 · high-value
Strategies for Switching between Oral Postsynaptic Antidopaminergic Antipsychotics in Patients with Schizophrenia: A Systematic Review.
CNS drugs · 2025 · high-value
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2025 · high-value
Trajectory of efficacy and safety across ulotaront dose levels in schizophrenia: a systematic review and dose-response meta-analysis.
The international journal of neuropsychopharmacology · 2025 · high-value
Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis.
The British journal of psychiatry : the journal of mental science · 2025 · high-value
Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study.
Schizophrenia research · 2024 · high-value
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet (London, England) · 2024 · high-value
Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Molecular psychiatry · 2023 · high-value
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.
Asian journal of psychiatry · 2023 · high-value
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Lancet (London, England) · 2022 · high-value
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2020 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
STUDY_DIRECTOR